

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 7/06, 7/08, A61K 37/02	A1	(11) International Publication Number: WO 95/00541 (43) International Publication Date: 5 January 1995 (05.01.95)
(21) International Application Number: PCT/GB94/01315 (22) International Filing Date: 17 June 1994 (17.06.94) (30) Priority Data: 9312601.9 18 June 1993 (18.06.93) GB 9409335.8 10 May 1994 (10.05.94) GB (71) Applicant (for all designated States except US): HAFSLUND NYCOMED A/S [NO/NO]; Slemdalsveien 37, N-0301 Oslo 3 (NO). (71) Applicant (for GB only): HOLMES, Michael, John [GB/GB]; 15 Campion Road, Putney, London SW15 6NN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): STEPHENS, Ross, W. [AU/NO]; Silurveien 19, N-0380 Oslo (NO). ORNING, Lars [SE/NO]; Thomas Heftyes gate 47B, N-0267 Oslo (NO). SAKARIASSEN, Kjell, S. [NO/NO]; Kygdø Alle 33B, N- 0262 Oslo (NO). (74) Agents: HOLMES, Michael, John et al.; Frank B Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: FACTOR VII-DERIVED PEPTIDES (57) Abstract The present invention relates to compounds comprising the amino acid sequences of the formulae (IA): -CVNENGCGCEQYCSD-, (IB): -FCLPAFEGRNCE- and/or (IC): -RCHEGYSLADGVSCT- as well as peptide fragments thereof, esters, amides, salts and cyclic derivatives thereof, functional analogues thereof and extended peptide chains carrying amino acids or peptides at the termini of the above sequences or fragments, for use in the prevention or inhibition of binding of tissue factor to FVII.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

FACTOR VII-DERIVED PEPTIDES.

5 The present invention is concerned with peptide reagents and compositions thereof which reduce blood clot formation.

10 Blood clotting relies upon a series or cascade of activating reactions to produce the ultimate fibrin clot. The cascade leading to fibrin formation may be triggered initially in two different ways - by contact with abnormal surfaces (the "intrinsic pathway") or by traumatization of blood vessels which causes secretion of the lipoprotein known as "tissue factor" or TF (the "extrinsic pathway"). The present invention is primarily concerned with the extrinsic blood clotting pathway.

15 TF is an integral membrane protein which appears on many cell types. However, cells which constitutively express TF, for example the muscle cells of vessels intima, are not normally exposed to blood (see Edgington et al., Thromb. Haemostas. 66(1): 67-69 (1991)). Thus initiation of the extrinsic blood clotting pathway appears to require either the disruption of blood vessel walls (see Almus et al., Blood 76: 354-360 (1990)) and/or activation of endothelial cells or monocytes to express TF (see Edwards et al., Blood 54: 359-370 (1979) and Bevilacqua et al., PNAS USA 83: 4533-4537 (1986)). Disruption of the blood vessel wall may occur due to fissuring of an atherosclerotic plaque which exposes tissue macrophages and smooth muscle cells to the blood (see Wilcox et al., PNAS USA 86: 2839-2843 (1989)). TF may also be exposed following injury to blood vessels during thrombolytic therapy, surgery for grafting, mechanical restoration of vessel patency or other similar techniques. On the other hand, TF expression in endothelial cells or in monocytes may be induced during sepsis due to production of tumour necrosis factor- α or

20
25
30
35

- 2 -

interleukin-1 (see Edwards et al., supra and Gregory et al., J. Clin. Invest. 76: 2440-2445 (1985)).

The serine protease Factor VIIa (FVIIa) is involved in the extrinsic blood clotting pathway. FVIIa is formed by proteolysis from its inactive pro-enzyme Factor VII (FVII) by other participants in the blood clotting process, including Factor Xa, Factor XIIa, Factor IXa or thrombin. Activation of FVII to FVIIa has been reported to be markedly enhanced when FVII is bound to its co-factor tissue factor (TF) (see Nemerson, Semin. Hematol. 29(3): 170-176 (1992)). Yamamoto et al. have also suggested that conversion of FVII to FVIIa may be autocatalytic (see J. Biol. Chem. 267(27): 19089-19094 (1992)).

FVIIa forms a complex with TF in the presence of calcium ions and the FVIIa/TF complex catalyses the conversion of Factor X to its active form, Factor Xa, in the next step of the blood clotting process via the extrinsic pathway.

The structure of FVII has been investigated and the cDNA sequence was reported by Hagen et al. in PNAS USA 83: 2412-2416 (1986). FVII is a vitamin K dependent protein and, by analogy to other vitamin K dependent proteins, a putative γ -carboxyglutamic acid (Gla) domain has been identified at the amino terminal. It was predicted, again by analogy to the other vitamin K proteins, that the Gla domain was required for binding to TF (see Hagen et al., supra). The Gla domain is followed by two potential growth factor (GF) domains. However, the literature has not suggested any function for the GF domains.

Activation of the extrinsic pathway for blood clot formation has been suggested as the primary event leading to fibrin formation (see Weiss et al., Blood 71: 629-635 (1988) and Weiss et al., Blood 73: 968-975 (1989)) and is thus of prime importance in the pathogenesis of arteriosclerotic lesions and in

- 3 -

reocclusion and and restenosis following endarterectomy. However effective therapeutic agents able to intervene in the activation of this pathway are not available, despite demand (see Shepard, TIBTECH 9: 80-85 (1991)).

The present invention provides peptides and analogues or salts thereof which inhibit the association of FVII or FVIIa with TF. Through the action of the peptides according to the invention, formation of the FVIIa/TF complex is limited and therefore activation of Factor X is reduced.

Certain peptides stated to be useful in blood clotting therapy are disclosed in WO-A-91/07432 of the Board of Regents, The University of Texas System. The peptides disclosed either occur in the region between the Gla and the first GF domains or in the catalytic domain of FVII or FVIIa. Although inhibition of FVIIa/TF complex formation is discussed, those peptides disclosed in WO-A-91/07432 which cause such an effect do so via inhibition of the Gla function. Such peptides are thus unspecific in their action since other physiological proteins have Gla domains, for example protein C which has close sequence homology to the Gla domain of FVII. Hence, the function of protein C would also be disturbed by peptides disclosed in WO-A-91/07432 in an undesirable way.

In WO-A-90/03390, Corvas Inc. suggest that certain peptides derived from the amino acid sequence of FVII (or FVIIa) might be useful in preventing the action of the fully formed FVIIa/TF complex. Two particular peptide sequences were disclosed in WO-A-90/03390 as being active in this respect. The sequence -VGHFGV- is based upon amino acids nos. 372-377 of FVII which are situated near the carboxy terminus. The other sequence is -SDHTGTKRSCR- which is located at amino acids nos. 103-113 of FVII and is part of the second GF domain. Corvas Inc indicate that these peptides, and analogues

- 4 -

thereof, inhibit the cascade reaction initiated by the FVIIa/TF complex.

Furthermore, in Table 1, on page 14 of W090/03390, it is indicated that of the various regions of the second GF domain, only SDHTGTKRSC (103 to 112) was active and that the other regions, namely from amino acids 50 to 101 and 114 to 127, were totally inactive in inhibition of activation of Factor X by Factor VII and tissue factor.

However, we have shown that, contrary to the reported findings of Corvas Inc., the region SDHTGTKRSC from 103 to 112 is a rather poor inhibitor of the binding of Factor VII to tissue factor and that certain of the regions said to be inactive are, in fact, highly active.

Our initial finding was that a point mutation in FVII, wherein the amino acid glutamine at position 100 was replaced by arginine, was observed in 16 FVII deficient Norwegian patients and suggested that this region of the FVII molecule is important for FVII activity. We established firstly that the amino acid sequence 91-102 was particularly active and that this could usefully also include amino acids 103 and 104. We then found that the amino acid sequence 114-127, also in the GF domain, was relatively active while the Corvas sequence 103-112 had only moderate activity.

Subsequently, we found that the amino acid sequence 72-81 acted synergistically in enhancing the inhibitory action of the peptides of the sequence 91 to 104, and primary utility of peptides derived from the region 72-81 is in such synergistic combinations.

Furthermore, fragments of the above sequences have been found to be inhibitory and in general fragments of 5 or more amino acids from the above sequences will be useful in the inhibition of FVII activity.

The present invention thus concerns peptides comprising the amino acid sequences of formulae

- 5 -

-CVNENGGCEQYCSD-	IA
-FCLPAFEGRNCE- and/or	IB
-RCHEGYSLLADGVSCT-	IC

as well as peptide fragments thereof, especially fragments having 5 or more amino acids, esters, amides salts and cyclic derivatives thereof, functional analogues thereof and extended peptide chains carrying amino acids or peptides at the termini of the above sequences or fragments.

According to one feature of the invention we provide peptides of the sequences IA, IB and/or IC as defined above, with the exclusion of the peptides

CVNENGGCEQYC	IIA
CLPAFEGRNC and	IIB
CHEGYSLLADGVSC	IIC

Where appropriate, compounds of formula IA, IB and IC and their various derivatives and fragments are termed, for convenience, peptide IA compounds, peptide IB compounds and peptide IC compounds.

Fragments of the peptide sequences of formulae IA, IB and/or IC include, in particular

-VNENG-	-NGGCEQYCSD-
-ENGGC-	-GGCEQYCSD-
-GGCEQ-	
-CEQYV-	

Our studies have shown that amino acid 95 is important in the peptides of the amino acid sequence 91 to 104 and the peptide of sequence 95 to 104 is the most active inhibitor so far tested. This is NGGCEQYCSD.

The peptides of formulae IIA, IIB and IIC are excluded on the basis that they were disclosed in W090/03390 of Corvas Inc., although stated to have zero

- 6 -

inhibitory activity. There is clearly no suggestion in W090/03390 that there would be any benefit in making any of the related peptides, including fragments or extensions thereof, for use in combatting blood clotting disorders.

On the basis that W090/03390 incorrectly reported zero inhibitory activity for the peptides of formulae IIA and IIB one aspect of the present invention provides the therapeutic or diagnostic use of the compounds of formulae IA and/or IB as defined above to bind to tissue factor and thus prevent or inhibit binding of tissue factor to FVII. In the case of peptide IC compounds, these will only be used together with peptide IA or IB compounds. For the sake of clarity, it is emphasised that compounds of formulae IIA, IIB and IIC are included in such use.

According to a further feature of the invention we provide the peptides of formulae IA and/or IB as defined above optionally in combination with peptides of formula IC as defined above.

According to a still further aspect of the invention we provide the use of the compounds of formulae IA and/or IB as defined above, optionally together with peptides of formula IC, for the preparation of pharmaceutical compositions for prevention or inhibition of binding of tissue factor to FVII.

As indicated above, the peptides of the sequence of formula IA are the most active but their activity can be enhanced synergistically by use together with peptides of formulae IB and/or IC and fragments and other derivatives thereof. In such combined use, the peptides may be simply mixed together or they may be covalently linked, for example via disulphide bonds between cysteine residues, or by spacer peptides.

Esters of the peptides of the invention include C₁₋₆ alkyl esters and readily cleaved ester groups such as

- 7 -

those listed hereinafter as protected carboxyl groups.

Amino acids or peptides attached to the termini of the peptides of the invention may carry functional groups such as protecting groups.

Salts of the peptides of the invention include physiologically acceptable salts such as acid addition salts such as hydrochlorides.

In the sequences referred to above, the standard one letter code is used to refer to each naturally occurring amino acid. This code is standard nomenclature within the art and can be found in any standard biochemical textbook such as "Biochemistry" Stryer, published by W.H. Freeman and Company.

Functional analogues of such peptides are included within the scope of the present invention. It is well known within the art that certain amino acids are functionally equivalent and it has frequently been observed that exchange of such equivalent peptides causes no diminution in protein function. Moreover, substitution of certain non-crucial amino acids may also be made without any, or any significant, loss of function - even where those amino acids have been replaced by chemically dissimilar amino acids. Further, chemical variants of the naturally occurring amino acids are known and substitution by such molecules is also covered by the term "analogue" as used herein.

In the sequence of formula I mentioned above any "C" representing the amino acid cysteine may be replaced by alanine (denoted by "A"). Thus, peptides which are of particular interest include -ENGGA-, -GGAEQ- and -AEQYV-.

Additionally, peptides derived from the sequence of formula IA, IB and/or IC include chimeric derivatives wherein two normally non-adjacent portions (containing two or more amino acids) of the formula I sequence are juxtaposed. An example of such a chimeric sequence is -EQYVNE-.

- 8 -

Optionally the peptides according to the invention may be cyclic, provided the sequence binding to TF is conformationally available for binding. Cyclisation may be achieved by any suitable chemical means including, for example, formation of disulphide bridges between two cysteine amino acids. One example of a cyclic peptide derived from formula I is CVNENGGCEQYC.

|_____|

The present invention also provides a pharmaceutical composition comprising one or more peptides or analogues or salts thereof, the amino acid sequence of said peptide comprising or being derived from the sequence of formula IA, IB and/or IC above. The peptides may be administered together with any physiologically acceptable excipient known to those skilled in the art, Examples of suitable excipients include water and oil.

The compositions according to the invention may be presented, for example, in a form suitable for oral, nasal, parenteral or rectal administration.

As used herein, the term "pharmaceutical" includes veterinary applications of the invention.

The compounds according to the invention may be presented in the conventional pharmacological forms of administration, such as tablets, coated tablets, nasal sprays, solutions, emulsions, powders, capsules or sustained release forms. Conventional pharmaceutical excipients as well as the usual methods of production may be employed for the preparation of these forms. Tablets may be produced, for example, by mixing the active ingredient or ingredients with known excipients, such as for example with diluents, such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talcum, and/or agents for obtaining sustained release, such as carboxypolymethylene, carboxymethyl

- 9 -

cellulose, cellulose acetate phthalate, or polyvinylacetate.

The tablets may if desired consist of several layers. Coated tablets may be produced by coating cores, obtained in a similar manner to the tablets, with agents commonly used for tablet coatings, for example, polyvinyl pyrrolidone or shellac, gum arabic, talcum, titanium dioxide or sugar. In order to obtain sustained release or to avoid incompatibilities, the core may consist of several layers too. The tablet-coat may also consist of several layers in order to obtain sustained release, in which case the excipients mentioned above for tablets may be used.

Organ specific carrier systems may also be used.

Injection solutions may, for example, be produced in the conventional manner, such as by the addition of preservation agents, such as p-hydroxybenzoates, or stabilizers, such as EDTA. The solutions are then filled into injection vials or ampoules.

Nasal sprays may be formulated similarly in aqueous solution and packed into spray containers either with an aerosol propellant or provided with means for manual compression. Capsules containing one or several active ingredients may be produced, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and filling the mixture into gelatin capsules.

Suitable suppositories may, for example, be produced by mixing the active ingredient or active ingredient combinations with the conventional carriers envisaged for this purpose, such as natural fats or polyethyleneglycol or derivatives thereof.

Dosage units containing the compounds of this invention preferably contain 0.1-10mg, for example 1-5mg of the peptide of formula (I) or salt thereof.

As indicated above, one aspect of the invention provides peptides (including the analogues or salts

- 10 -

thereof) according to the invention for use in the treatment or prevention of blood clotting disorders or problems. Blood clotting disorders include thrombosis (particularly vascular thrombosis or deep vein thrombosis), acute myocardial infarction, restenosis, reclosure, angina, cerebrovascular disease, peripheral arterial occlusive disease, hypercoagulability and pulmonary embolism. The peptides according to the invention can also be used to prevent occurrence of blood clotting problems caused by, for example, injury to blood vessels during thrombolytic therapy, grafting surgery, vessel patency restoration etc. Blood clotting disorders may be triggered by sepsis due to production of $\text{TNF-}\alpha$ or IL-1.

In a still further aspect, the present invention also provides a method of treatment of blood disorders in the mammalian, preferably human, animal body, said method comprising administering to said body one or more peptides of formula IA, IB and/or IC as defined above, including compounds of formulae IIA, IIB and/or IIC, or analogues or salts thereof. Prophylactic methods of treatment are also provided, whereby a peptide according to the invention is administered to a patient to prevent or reduce the occurrence of possible blood clotting problems, for example during surgery or other invasive techniques. The peptide will of course normally be administered in the form of a pharmaceutically acceptable composition.

In another aspect, the present invention provides a process for the preparation of peptides which comprise the sequence of formula I or are derived therefrom, or analogues or salts thereof.

The peptides of the invention may be synthesised in any convenient way. Generally the reactive groups present (for example amino, thiol and/or carboxyl) will be protected during overall synthesis. The final step in the synthesis will thus be the deprotection of a

- 11 -

protected derivative of the peptide of the invention.

In building up the peptide chains, one can in principle, start either at the C-terminal or the N-terminal although only the C-terminal starting procedure is in common use.

Thus, one can start at the C-terminal by reaction of a suitably protected derivative of, for example lysine with a suitably protected derivative of cysteine or cystine. The lysine derivative will have a free α -amino group while the other reactant will have either a free or activated carboxyl group and a protected amino group. After coupling, the intermediate may be purified, for example by chromatography, and then selectively N-deprotected to permit addition of a further amino acid residue. This procedure is continued until the required amino acid sequence is completed.

Carboxylic acid activating substituents which may, for example, be employed include symmetrical or mixed anhydrides, or activated esters such as for example the p-nitrophenyl ester, 2,4,5-trichlorophenyl ester, N-hydroxybenzotriazole ester (OBt), or N-hydroxy-succinimidyl ester (OSu).

The coupling of free amino and carboxyl groups may, for example, be effected using dicyclohexylcarbodiimide (DCC). Another coupling agent which may, for example, be employed is N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.

In general it is convenient to effect the coupling reactions at low temperatures, for example, -20°C up to ambient temperature, conveniently in a suitable solvent system, for example, tetrahydrofuran, dioxan, dimethylformamide, methylene chloride or a mixture of these solvents.

It may be more convenient to carry out the synthesis on a solid phase resin support. Chloromethylated polystyrene (cross-linked with 1% divinyl benzene) is one useful type of support; in this case

- 12 -

the synthesis will start at the C-terminal, for example by coupling N-protected lysine to the support.

A number of suitable solid phase techniques are described by Eric Atherton, Christopher J. Logan, and Robert C. Sheppard *J. Chem.Soc. Perkin I*, 538-46 (1981); James P. Tam, Foe S. Tjoeng, and R. B. Merrifield *J. Am. Chem. Soc.* 102 6117-27 (1980); James P. Tam, Richard D. Dimarchi and R. B. Merrifield *Int. J. Peptide Protein Res* 16 412-25 (1980); Manfred Mutter and Dieter Bellof, *Helvetica Chimica Acta* 67 2009-16 (1984).

A wide choice of protecting groups for amino-acids are known and are exemplified in Schröder, E., and Lübke, K., *The Peptides*, Vols. 1 and 2, Academic Press, New York and London, 1965 and 1966; Pettit, G.R., *Synthetic Peptides*, Vols. 1-4, Van Nostrand, Reinhold, New York 1970, 1971, 1975 and 1976; Houben-Weyl, *Methoden der Organischen Chemie, Synthese von Peptiden*, Band 15, Georg Thieme Verlag, Stuttgart 1974; *Amino Acids, Peptides and Proteins*, Vol.4-8, The Chemical Society, London 1972, 1974, 1975 and 1976; *Peptides, Synthesis-physical data* 1-6, Wolfgang Voelter, Eric Schmidt-Siegmán, Georg Thieme Verlage Stuttgart, NY, 1983; *The Peptides, Analysis, synthesis, biology* 1-7, Ed: Erhard Gross, Johannes Meienhofer, Academic Press, NY, San Fransisco, London; *Solid phase peptide synthesis* 2nd ed., John M. Stewart, Janis D. Young, Pierce Chemical Company.

Thus, for example amine protecting groups which may be employed include protecting groups such as carbobenzoxy (hereinafter also designated Z) t-butoxycarbonyl (hereinafter also designated Boc), 4-methoxy-2,3,6-trimethylbenzene sulphonyl (Mtr) and 9-fluorenylmethoxycarbonyl (hereinafter also designated Fmoc). It will be appreciated that when the peptide is built up from the C-terminal end, an amine-protecting group will be present on the α -amino group of each new

- 13 -

residue added and will need to be removed selectively prior to the next coupling step. One particularly useful group for such temporary amine protection is the Fmoc group which can be removed selectively by treatment with piperidine in an organic solvent.

Carboxyl protecting groups which may, for example be employed include readily cleaved ester groups such as benzyl (Bzl), p-nitrobenzyl (ONb), pentachlorophenyl (OPClP), pentafluorophenyl (OPFP) or t-butyl (OtBu) groups as well as the coupling groups on solid supports, for example methyl groups linked to polystyrene.

Thiol protecting groups include p-methoxybenzyl (Mob), trityl (Trt) and acetamidomethyl (Acm).

It will be appreciated that a wide range of other such groups exists as, for example, detailed in the above-mentioned literature references, and the use of all such groups in the hereinbefore described processes fall within the scope of the present invention.

A wide range of procedures exists for removing amine- and carboxyl-protecting groups. These must, however, be consistent with the synthetic strategy employed. The side chain protecting groups must be stable to the conditions used to remove the temporary α -amino protecting group prior to the next coupling step.

Amine protecting groups such as Boc and carboxyl protecting groups such as tBu may be removed simultaneously by acid treatment, for example with trifluoro acetic acid. Thiol protecting groups such as Trt may be removed selectively using an oxidation agent such as iodine.

The following Examples are given by way of illustration only.

Figure 1 illustrates the inhibition of blood clotting by different FVII peptides and FVII peptide analogues.

Figure 2 shows the dose-response relationship

- 14 -

between FVII/TF activity and the peptide FVII-5.

Figure 3 is the dose-response relationship between FVII/TF activity and the peptide FVII-5d.

Figure 4 shows the inhibition of Factor X activation at different concentrations of FVII-5.

The present invention is further illustrated by the following, non-limiting, examples.

The following abbreviations are used in the Examples:

TFA : trifluoroacetic acid
BocAA : t-butoxy carbonyl protected Amino acid
BOP : benzotriazol-1-yloxy-tris-(dimethylamino) -
phosphonium-hexafluorophosphate
HOBT : N-hydroxybenzotriazole
DIEA : diisopropylethylamine
DCM : dichloromethane
NEM : N-ethylmaleimide
EDTA : ethylenediaminetetraacetic acid
DMF : dimethylformamide

EXAMPLE 1

General Peptide Synthesis

The peptides used were synthesized by standard procedures of solid phase chemistry and purified by preparative HPLC. The purity of each peptide was checked by analytical HPLC, amino acid analysis and mass spectrometry. All were products of Neosystems Laboratoire (Strasbourg, France).

The peptides were assembled and cleaved using the following general procedure.

- 15 -

The resin used was 4-methylbenzhydrylamine (batch R2161) with an initial loading of 0.9 meq/g. For each peptide 450 mg of starting resin (0.4 mmol) was used.

1. Assembling

After neutralisation, the coupling/deprotection protocol described below was used (volume: 10 ml for each solvent).

- | | |
|---------------------------------|-------------------|
| a) Neat TFA | 1 min. |
| b) Neat TFA | 3 min. |
| c) Flow wash methylene chloride | |
| d) Isopropanol | 0.5 min. |
| e) Dimethylformamide (DMF) | 0.5 min (3 times) |
| f) Dimethylformamide flow wash | |

Coupling

5 eq. of BocAA, BOP and HOBt were dissolved in 5 ml of DMF and added to the resin. After bubbling started 0.5 ml of diisopropylethylamine was added and agitation was continued for 13 minutes. After 2 DMF washes a double coupling was performed in the same conditions.

Acetylation

After the last deprotection step, acetylation was performed using 10 eq. of acetic anhydride and 10 eq. of DIEA in 10 ml of DMF.

Reaction time: 10 minutes.

Once assembling was achieved, the peptide resin was washed with DMF, DCM ether and then dried under nitrogen stream.

- 16 -

2. Cleavage

The peptide was cleaved from the resin and deprotected by a treatment with HF/anisole (9/1 by volume. 10 ml per gram of peptide resin) at 0°C for 45 minutes.

After evaporation of the HF and precipitation with ether, the crude peptide was solubilised in neat TFA and filtered.

The TFA was then evaporated under reduced pressure and the peptide was again precipitated with ether. At this stage the product was ready to be purified.

3. Purification and analysis

Each peptide was HPLC purified on reversed phase C₁₈ column (15-25µm) using a linear gradient of acetonitrile/ water (0.1 % TFA). The fractions with a purity >95% were pooled and lyophilised. The purified peptide was then analysed by HPLC and a sample was hydrolyzed for amino acid analysis. The results were noted on the analytical data sheet which was sent with each peptide.

The basic strategy used for purification was always the same. Only the gradient used for the preparative purification was different, depending on the initial retention time of each individual peptide.

EXAMPLE 2

PEPTIDE FVII-5

The resin used was Boc-Cys(4-MeBzl)-PAM resin (batch 52172) with an initial loading of 0.63 meq/g. 0.96 g of

- 17 -

the starting resin (0.6 mmol) was used.

The assembling/coupling/cleavage procedure used was the same as described above, with the following modifications:

1. Assembling

- | | |
|-------------------|---------|
| a) TFA 55% in DCM | 5 min. |
| b) TFA 55% in DCM | 25 min. |

2. Cleavage

After precipitation with ether, the peptide resin was washed with 30 ml 10% acetic acid in water and lyophilised.

3. Purification - cyclisation

Solvent composition :

A : water 0.1% TFA

B : acetonitrile/solvent A (60/40 by volume).

The crude product was pre-purified on reversed phase HPLC using a linear gradient of acetonitrile/water (0.1% TFA), 10 to 80% of B, 30 minutes.

All the fractions containing the linear peptide with a purity > 80 were pooled and the volume was adjusted to 0.5 litre with water. The pH of the solution was adjusted to 8.5 with DIEA and left overnight at ambient temperature, under magnetic stirring. The evolution of the cyclisation reaction was followed by co-injection of a sample of the reaction mixture with N-ethylmaleimide (NEM).

- 18 -

After 24 hours, cyclisation was complete. The pH was then decreased to 2.5 with acetic acid and the solution concentrated under reduced pressure before lyophilisation.

The cyclic peptide was then purified up to 95% by RP - HPLC (linear gradient from 5 to 30% of B in 30 minutes).

Purity and identity of the final product were then controlled by analytical HPLC, amino acid analysis and mass spectrometry.

EXAMPLE 3

PEPTIDE FVII-1

This peptide was synthesised using Fmoc/t-But strategy starting from 90 mg of Fmoc-Ala-Wang resin (0.67 meq/g).

1. Assembling

The following protocol was used for deprotection/coupling :

- | | | |
|----|-----------------------|-----------------|
| a) | Piperidine 25% in DMF | 2 min. |
| b) | Flow wash DMF | |
| c) | Piperidine 25% in DMF | 4 min. |
| d) | Flow wash DMF | |
| e) | Piperidine 25% in DMF | 6 min. |
| f) | Flow wash DMF | repeat 5 times. |

2. Coupling

5 eq. of Fmoc-AA, BOP and HOBT were dissolved in 3 ml of DMF and added to the resin. After bubbling started,

- 19 -

0.13 ml of DIEA was added and coupling was continued for 13 minutes. After 2 DMF washes, a double coupling was performed as described above.

3. Cleavage

Cleavage of the peptide and deprotection were achieved by a treatment with 5 ml of a mixture of TFA (83.3 %), water (4.2%), thioanisole (4.2%), ethanedithiol (2.1 %) and phenol (6.25%) for 2.5 hours. After filtration this mixture was poured into 25 ml of cold ether. The precipitated peptide was centrifuged and washed twice with ether. The product was then dissolved in water, lyophilized and used without further purification.

EXAMPLE 4

Other synthetic peptides were produced by analogy to the procedure described in Example 1.

Table 1 lists all the peptides synthesised.

TABLE 1 - FACTOR VII PEPTIDES

<u>DESIGNATION</u>	<u>SEQUENCE</u>	<u>RESIDUES IN FVII</u>
FVII-12	LFWISYSD	39-46
FVII-21	WISYSDGD	41-48
FVII-23	SYSDGD	43-48
FVII-2	YSDGDQC	44-50
FVII-7(cyclic)	CASSPCQNGGSC	50-61
FVII-13	KDQLQSYI	62-69
FVII-8(cyclic)	CLPAFEGRNC	72-81
FVII-9	NCETHKDDQLICV	80-92

- 20 -

FVII-5 (linear)	CVNENGGCEQYC	91-102
FVII-5 (cyclic)	CVNENGGCEQYC	91-102
5A	VNENG	92-96
5B	ENGGA	94-98
5C	GGAEQ	96-100
5D	AEQYV	98-102
5E	EQYVNE	99-101+92-94
FVII-10	NGGCEQYCSD	95-104
FVII-10A	GGCEQYCSD	96-104
FVII-10B	GCEQYCSD	97-104
FVII-10C	CEQYCSD	98-104
FVII-10D	EQYCSD	99-104
FVII-4	SDHTGTRKSCR	103-113
FVII-4B	SDHTGTRKRS	103-111
FVII-6 (cyclic)	CHEGYSLLDGVSC	114-127
FVII-1	GKIPILEKRNA	136-146
FVII-11	DKIKNWRNLIA	196-206
FVII-3	VGHFGV	371-376

EXAMPLE 5Assay of FVIIa/TF activity

Peptides (0-1 mM) were preincubated in 0.1 M Tris.HCl pH 7.2 with tissue factor (Thromborel®, Behringwerk, Marburg, Germany; 0.2% final concentration) at 22°C for 30 minutes, then Factor X (American Diagnostica Inc., Greenwich, CT USA; 70 nM was added followed by FVIIa (Diagnostica Stago, Asnières, France; 8 pM and CaCl₂ (5 mM). Incubations were continued for 30 minutes and quenched with EDTA (50 mM) which removes essential Ca²⁺. The FXa produced was quantified by monitoring hydrolysis of the chromogenic FX substrate S-2222 (Chromogenix, Mölndal, Sweden).

The results are shown in Figure 1.

- 21 -

EXAMPLE 6

The effect of different concentrations of the peptide FVII-5 was investigated using the assay procedure described in Example 5. The experiment was repeated using the peptide FVII-5D.

The results are shown in Figures 2 and 3 respectively.

EXAMPLE 7

The kinetics of inhibition of FX activation by FVII-5 was investigated. Varying concentrations of FVII-5 were incubated with different concentrations of Factor X in the presence or absence of TF and FVIIa.

The results are shown in Figure 4. Both graphs are based upon the same data and both indicate a non-competitive inhibition of Factor X activation by FVII-5 thus indicating that inhibition occurs at an earlier step than Factor X binding ie. inhibition occurs at FVIIa/TF complex formation.

EXAMPLE 8Assay of apoTF/FVIIa Catalytic Activity

This colorimetric assay was used to measure directly the amidolytic (catalytic) activity of purified human FVIIa when bound to recombinant human TF in the absence of phospholipid.

PROTOCOL

Reactions were performed in microtitre plate wells,

- 22 -

using a final incubation volume of 200 uL. Test compounds, dissolved in water, (final concentration, 0-1 mM) were preincubated with recombinant human tissue factor (American Diagnostica; cat# 4500; 5 nM) and CaCl_2 (5 mM) in Tris buffer (100 mM), pH 7.2, containing NaCl (150 mM) and BSA (1 mg/mL) at ambient temperature for 30 minutes. Factor VIIa (Enzyme Research Laboratories, cat# HFVIIa; 5 nM) was added and the incubations continued for 60 minutes. Chromogenic substrate, S2288 (Chromogenix cat# 820852; 0.5 mM) was then added and the enzymatic activity of the tissue factor apoprotein/factor VII complex (apoTF/FVIIa) was monitored at 405 nm.

EXAMPLE 9

Assay of HT1080 Cell Surface TF/FVIIa Mediated Activation of FX

This assay system was used to measure the catalytic activity of native TF/FVIIa complex on the surface of living cells expressing TF in their cell membrane. The activity was measured as the amidolytic (catalytic) activity of FXa produced by the action of the cell surface TF/FVIIa on added FX. The cell line chosen for this assay was the human fibrosarcoma HT-1080 (American Type Culture Collection CCL 121).

PROTOCOL

HT-1080 cells were suspended in a small volume of serum-containing medium and mixed with microcarriers (Cytodex-3, Pharmacia) in a ratio of about 50-100 cells/ micro-carrier. The cells were usually adherent on the microcarriers within 2 h and could then be transferred to normal roller bottles with a larger volume of culture

- 23 -

medium. The microcarrier cell preparations were then washed twice in calcium free buffer to remove bound serum factors. Of nine different washing buffers tested, 'Hank's buffered salt solution' was found to be optimal when considering i) low carry-over of serum factors, ii) small effect on cell adhesion to microcarrier spheres, iii) little damage to cell membranes, and iv) high cell surface TF activity. The microcarrier spheres were resuspended in Hank's buffer and the beads were counted.

FVII (Enzyme Research Laboratories cat# HVLI 1007; 5 pM) (and inhibitor in inhibition assays) was then added and the mixture allowed to equilibrate for 30 minutes before addition of FX (Enzyme Research Laboratories cat# HFX 1010; 50 nM) and CaCl_2 (5 mM). The rate of FX formation was determined by an amidolytic assay using chromogenic substrate S2765 for FXa (Chromogenix cat# 821413) and measurement of the absorbance increase at 405 nm. The TF activity was easily adjusted by simple dilution of the microcarrier suspension. The variation could be kept at a minimum by stirring the suspension when aliquots were removed. It was determined as $14 \pm 7\%$.

That FX activation by the cells was truly dependent upon cell-surface TF could be shown by the use of a neutralizing monoclonal antibody to human TF as depicted in Fig 5. Titration of cell-bound TF with FVII indicated about 11,000 TF molecules per cell or 0.8 ng/ 10^6 cells. Also FX activation was dependent on incubation time and FVII added (Fig. 6 & 7). That the activity measured represented FXa was verified by inhibition of activity with TAP (tick anticoagulant polypeptide; G. Vlasuk, Corvas Int.) (Fig. 8).

FIGURE LEGENDS

Fig. 5 Inhibition of the cell mediated activation of factor X by a neutralizing monoclonal antibody to tissue factor (American Diagnostica #4504). HT-1080 cells and antibody were preincubated for 1 hour at room temperature before the addition of factor VII (5 pM) and factor X (56 nM). Reactions were continued for 2 hours and quenched by the addition of EDTA. Formation of factor Xa was monitored by an amidolytic assay using a factor Xa chromogenic substrate (Chromogenix, S2765). Inhibition reached >95% indicating complete dependence on tissue factor.

Fig. 6 Time course for factor X activation using 0 (■) and 1 nM (●) factor VII.

Fig. 7 Dependence of cell mediated factor X activation on added factor VII. Mean of triplicate determinations. Intra-assay variation was 12±14%.

Fig. 8 Inhibition by TAP (tick anticoagulant polypeptide) of FXa amidolytic activity generated by HT-1080 cell-surface TF/FVIIa.

EXAMPLE 10

Assay of Cell-surface TF Initiated Coagulation of Plasma

A novel assay system has been devised to measure the coagulation of blood plasma (i.e. clotting time) induced by tissue factor (TF) expressed on the surface of living cells. This assay makes use of human or animal cells adherent on the surface of microcarriers (see Fig 9), which enables reproducible presentation of known amounts

- 25 -

of TF activity in the stirred measuring well of an electromagnetic coagulometer. The cells used may be normal or transformed, and representing phenotypes such as monocytes, endothelium, fibroblasts etc (see Fig 10).

This novel assay has been particularly developed and characterised so as to be highly useful in determining the effect of synthetic peptides and peptidomimetic compounds on the extrinsic pathway of coagulation, using living cells in a plasma milieu. Results for the inhibitory effect of synthetic peptides based upon the amino acid sequence of human FVII are disclosed.

PROTOCOL

The microcarrier cell preparation is made as follows. Cells obtained from primary isolates or subcultures of transformed lines (see Fig. 10) are suspended in a small volume of serum-containing medium and mixed with microcarriers (Cytodex-3, Pharmacia) in a ratio of about 50-100 cells/microcarrier. The cells are usually adherent on the microcarriers within 2 hours, and can then be transferred to normal roller bottles with a larger volume of culture medium. Uniform coverage of microcarriers with about 20-60 cells can be obtained directly with transformed cells, when large cell numbers are available, or after 2 days growth when primary cultures (e.g. umbilical vein endothelial cells) are used. Primary cultures of cells not expressing TF (e.g. monocytes or endothelial cells) may be stimulated to express TF by incubation of the adherent cells with such agents as bacterial lipopolysaccharide (LPS) or tumour necrosis factor-alpha (TNF- α) (see Fig. 10).

To assay the extrinsic coagulation activity, the microcarrier cell preparations are first washed with a calcium-free buffer to remove bound serum factors. A

- 26 -

calcium-containing buffer and plasma are then added and the clotting time is determined automatically in an electromagnetic coagulometer. The clotting time may be very conveniently adjusted (e.g. 35 sec) by simple dilution of the microcarrier suspension, and reproducibility is easily obtained provided the suspension is stirred when aliquots are removed. The clotting time may be converted to arbitrary TF units by a log-log calibration curve generated with rabbit brain thromboplastin.

The system obtained can be shown to faithfully represent the extrinsic pathway of coagulation, by the use of a panel of immunodepleted human plasmas deficient in each of the coagulation factors. Coagulation mediated by e.g. ECV304 human endothelial cells (American Culture Collection CRL-1998) is clearly dependent on FVII and FX (Fig. 11). Thus there is no direct activation of FX; the coagulation is mediated by cell-surface TF/FVII. That this procoagulant activity really represents TF-mediated coagulation was demonstrated by the use of a neutralising monoclonal antibody to human TF, which could abolish all coagulation activity (Fig 12).

FIGURE LEGENDS

Fig. 9 Principle of the microcarrier assay of cell-surface mediated coagulation of blood plasma. Living cells (e.g. human HT-1080 fibrosarcoma; ATCC CRL 121) adherent on the surface of microcarriers are mixed with a calcium-containing buffer and plasma in the incubation well of a Thrombotrack™ electromagnetic coagulometer (Nycomed). The clotting time is measured by the increase in resistance to movement of a magnetic ball produced by the formation of fibrin fibres. HT-1080 cells

- 27 -

adherent on Cytodex-3 microcarriers are shown in the lower inset as an example of the types of cells expressing TF which may be used.

Fig. 10 Coagulant activity of a selection of cell types adherent on microcarriers. The activity is expressed as TF units per 10^5 cells, calculated from a calibration curve generated with rabbit brain thromboplastin (Nycomed). The cell types shown are: RD, human rhabdomyosarcoma cells (ATCC CCL 136); HT-1080, human fibrosarcoma cells (ATCC CRL 121); HE US, unstimulated primary culture of human umbilical vein endothelial cells; HE ST, human umbilical vein endothelial cells after stimulation with bacterial lipopolysaccharide ($1 \mu\text{g/ml}$; 5 h); ECV-304, human endothelial cells (ATCC CRL 1998); HM US, unstimulated human peripheral monocytes and HM ST, human peripheral monocytes after stimulation with bacterial lipopolysaccharide ($0.5 \mu\text{g/ml}$; 2 h).

Fig. 11 Dependence of ECV-304 mediated coagulation on specific coagulation factors, demonstrated by the use of immunodepleted human plasmas (American Diagnostica) in the microcarrier assay. Note complete dependence on factors VII and X.

Fig. 12 Characterisation of the coagulant activity on ECV-304 cells in the microcarrier assay by the use of a neutralising monoclonal antibody to human TF (American Diagnostica cat#4504). Almost all clotting activity can be abolished by the neutralising antibody, thus demonstrating that it is highly dependent on the function of TF.

- 28 -

EXAMPLE 11

Inhibition of TF/FVII Assay by FVII Peptides

ELISA Assay

The inhibition results shown in Fig. 13 indicate that in addition to sequences from the "hinge" region (i.e. residues 41-48 between the GLA domain and the first EGF domain, UNIVERSITY OF TEXAS) and from the first EGF domain itself (i.e. residues 50-61; Clarke et al), there exist additional sequences in the second EGF domain (especially 95-104) which are inhibitors when presented as peptides in this binding assay. Peptide 95-104 was considerably better as an inhibitor in this assay than 103-111 (CORVAS Int.)

Colorimetric Assay of apoTF/FVIIa Amidolytic Activity

Tests using this type of assay further demonstrated that the peptide representing residues 95-104 of human FVII is a good inhibitor of TF/FVII complex formation, and better than the peptide 103-111 (CORVAS Int.) (see Figs. 14 and 15). Note that residue 95 was an important contributor to the inhibitory properties of the peptide 95-104, shown by the very low activity of peptide 96-104 compared to peptide 95-104 (Fig.14). Synergism was also apparent when certain peptide mixtures were tested as inhibitors, e.g. a mixture of 95-104 and 72-81 (see Fig. 16). Kinetic experiments demonstrated that inhibition by peptide 95-104 was non-competitive with respect to the catalytic site of FVIIa (see Fig. 17), consistent with inhibition of TF/FVII complex formation rather than direct inhibition of FVIIa's enzyme activity.

- 29 -

Activation of FX by Cell-Surface TF/FVIIa

Peptide 95-104 was clearly the best inhibitory peptide of those tested in this assay also, and considerably better than 103-111 (CORVAS Int.) (Fig. 18). Note that residues 95-97 were important contributors to the inhibitory properties of the peptide 95-104.

Coagulation Initiated by Cell-Surface TF/FVIIa

This assay system differed critically from those above in that the reaction mixture contained whole human plasma, and therefore represented considerably more closely the environment of the luminal surface of an endothelial cell in vivo. In this system also, peptide 95-104 was a good inhibitor, followed by 41-48 (TEXAS UNIVERSITY) and 91-102 (Fig. 19). The inhibitory effect of 95-104 was also clearly dependent on residue 95. Note that 114-127 was a moderate inhibitor. Once again, 95-104 was a considerably better inhibitor than 103-111 (CORVAS Int.) in this system also (Fig. 20).

FIGURE LEGENDS

Fig. 13 ELISA assay of the inhibition of FVII binding to immobilized rTF produced by synthetic FVII peptides (all at 0.5 mM). For peptide sequences see the table of peptides above (page 19). C and L denote the cyclic and linear forms respectively of peptides with terminal cysteines.

Fig. 14 Colorimetric assay of the inhibition of apoTF/FVIIa amidolytic activity produced by synthetic FVII peptides (all at 0.5 mM). C and L denote the cyclic and linear forms respectively of peptides with terminal

- 30 -

cysteines.

Fig. 15 Inhibition of apoTF/FVIIa amidolytic activity by FVII peptide sequences selected by Bioreg (95-104) and Corvas Int (103-111).

Fig. 16 Synergistic inhibition of apoTF/FVIIa amidolytic activity. The figure shows inhibition with 95-104 alone (■), with a mixture of 95-104 and a fixed concentration (0.5 mM) of 72-81 (Δ) and with 0.5 mM 72-81 alone (●). The theoretical (additive) effect of an equimolar mixture of the two peptides is indicated by a solid line without symbols.

Fig. 17 Kinetic experiment analysing mode of inhibition of apoTF/FVII activity by peptide 95-104. This inhibition is clearly non-competitive, thus demonstrating that the inhibition observed is not mediated by an effect on the active site of FVIIa.

Fig. 18 FVII peptide inhibition of activation of FX by TF/FVIIa on the surface of HT-1080 cells. Results are shown for each peptide at 0.5 mM.

Fig. 19 The effect of a selection of synthetic FVII peptides (all at 0.5 mM) on the coagulation of plasma by TF/FVIIa on the surface of HT-1080 and ECV304 cells. The peptide numbers shown refer to the amino acid sequence of human FVII; C and L denote the cyclic and linear forms respectively of peptides with terminal cysteines.

Fig. 20 Inhibition of ECV-304 cell-surface TF mediated coagulation by synthetic FVII peptide sequences

- 31 -

selected by Bioreg (95-104) and Corvas Int (103-111).

The results of the above peptide inhibition experiments are tabulated below:

Summary of Peptide Inhibition Results

FVII peptide IC₅₀ (mM) or % inhibition at 0.5 mM^a

Sequence ^b	Amidolytic apo TF Assay	Amidolytic Microcarrier assay	ELISA binding assay	Coagulation microcarrier assay
72-81 (C)	2.40	0.35	89%	(22 %)
91-102 (C)	0.60		0.04	0.58
91-102 (L)	1.14		0.06	(14 %)
91-102 (anal) ^c	1.30		0.05	1.50
95-104	0.38	0.13	0.03	0.40
96-104	0.92		0.08	(27 %)
98-102				(17 %)
103-111	2.20	0.87	59%	(30 %)
114-127 (C)	(21 %)		(77 %)	(44 %)

^a) Percent inhibition at 0.5 mM is given for those peptides which did not reach quantitative or near-quantitative inhibition at the highest test concentration (1 mM).

^b) The sequence numbers given are with reference to the native sequence of human FVII. C and L refer to the disulfide cyclised and linear forms respectively.

^c) 91-102 (anal) has an arginine residue at position 100, in place of glutamine.

EXAMPLE 12

Validation of Specificity of Peptide Inhibitors

The effect of the peptides observed in the coagulation assay could conceivably have been due to effects on another one or more of the several components contributing to the coagulation cascade. This possibility was therefore tested by adding the peptides to coagulation assays which were initiated by contact activation (Cephotest™, Nycomed), and therefore involved coagulation factors of the intrinsic and common pathways of coagulation, i.e. all coagulation factors other than TF/FVII. The peptides 95-104, 91-102 and 103-111 were inactive in this system, while control inhibitors of FX (TAP) and thrombin (Hirudin; HIR) were strongly inhibitory (see Fig. 21 below). Thus evidence was obtained that the effects observed in the TF/FVII initiated coagulation assay above were in fact due to a direct effect on the TF/FVII complex.

- 33 -

Claims

1. Compounds comprising the amino acid sequences of formulae

5 -CVNENGGCEQYCSD- IA
 -FCLPAFEGRNCE- and/or IB
 -RCHEGYSLLDGVSCT- IC

as well as peptide fragments thereof, esters, amides,
10 salts and cyclic derivatives thereof, functional
analogues thereof and extended peptide chains carrying
amino acids or peptides at the termini of the above
sequences or fragments, for use in the prevention or
inhibition of binding of tissue factor to FVII.

15

2. Compounds comprising the amino acid sequences of formulae

 -CVNENGGCEQYCSD- IA
 -FCLPAFEGRNCE- and/or IB
20 -RCHEGYSLLDGVSCT- IC

as well as peptide fragments thereof, esters, amides,
salts and cyclic derivatives thereof, functional
analogues thereof and extended peptide chains carrying
25 amino acids or peptides at the termini of the above
sequences or fragments with the exclusion of the
peptides

 CVNENGGCEQYC IIA
30 CLPAFEGRNC and IIB
 CHEGYSLLDGVSC IIC.

3. Compounds as claimed in claim 1 or claim 2
comprising 5 or more amino acids.

35

- 34 -

4. Compounds as claimed in any one of claims 1 to 3 being -VNENG-, -ENGGC-, -GGCEQ-, -CEQYV-, -NGGCEQYCSD- or -GGCEQYCSD-.
- 5 5. Compounds as claimed in any one of claims 1 to 3 being -ENGGA-, -GGAEQ- or -AEQYV-.
6. A compound as claimed in any one of claims 1 to 3 being -EQYVNE-.
- 10 7. Compounds as claimed in any one of claims 1 to 3 being cyclic derivatives thereof.
- 15 8. Use of compounds of formulae IA and/or IB as defined in claim 1, optionally together with compounds of formula IC, for the preparation of pharmaceutical compositions for prevention or inhibition of binding of FVII to tissue factor.
- 20 9. Use of compounds of formulae IA and/or IB, optionally together with compounds of formula IC, for the prevention or inhibition of binding of FVII to tissue factor.
- 25 10. Use as claimed in claim 8 or claim 9, wherein the compounds of formula IA, IB and IC comprise 5 or more amino acids.
- 30 11. Pharmaceutical compositions comprising one or more peptides or analogues or salts thereof, the amino acid sequence of said peptide comprising or being derived from the sequence of formula IA, IB and/or IC as defined in claim 1 together with a physiologically acceptable excipient.
- 35 12. A method of treatment of the human or animal body to combat or prevent blood disorders said method

- 35 -



comprising administering to said body one or more peptides of formula IA, IB and/or IC as defined in claim 1 or analogues or salts thereof.

- 5 13. A process for the preparation of compounds of formula IA, IB and/or IC as defined in claim 1, said process comprising the step of deprotecting a protected derivative of a compound of formula IA, IB and/or IC.

Figure 1

1/21


Inhibitory effect of synthetic factor VII peptide analogs on
factor VII/ tissue factor activity



2/21


Figure 2

Inhibition of factor VII/TF activity by cyclic peptide VII-5



3/21



Figure 3
Inhibition of factor VII/TF activity by VII-5D



4/21

Figure 4


Inhibition of FX activation by VII-5 as a function of FX concentration



5/21


FIGURE 5

INHIBITION OF HT-1080 MEDIATED FXa
FORMATION BY ANTI-TF MAb#4504




6/21

FIGURE 6



7/21


FIGURE 7



8/21


FIGURE 8

TAP INHIBITION OF FXa PRODUCED BY TF/FVIIa
ON HT-1080 CELL-SURFACE




9/21

FIGURE 9

MICROCARRIER ASSAY OF CELL SURFACE TF
MEDIATED COAGULATION OF BLOOD PLASMAHT-1080 CELLS ADHERENT ON
A CYTODEX-3 MICROCARRIER

10/21


FIGURE 10



11/21

FIGURE II


EFFECT OF SPECIFIC DEPLETION OF COAGULATION
FACTORS ON ECV-304 TF MEDIATED COAGULATION



12 /21


FIGURE 12

INHIBITION OF ECV-304 MEDIATED COAGULATION BY
MONOCLONAL ANTI-TF ANTIBODY AD 4504




13/21

FIGURE 13




14/21

FIGURE 14



15/21


FIGURE 15



16/21

FIGURE 16


Inhibition of apoTF/VIIa activity:
Synergy between 95-104 and 72-81(C)



17/21


FIGURE 17

EFFECT OF PEPTIDE 95-104 ON APO-TF/FVIIa
DEPENDENT HYDROLYSIS OF S2288




18/21

FIGURE 18




19/21

FIGURE 19

EFFECT OF FVII PEPTIDES IN CELL MEDIATED
COAGULATION ASSAY


20/21

FIGURE 20



21/21

FIGURE 21



INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 94/01315A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07K7/06 C07K7/08 A61K37/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 09804 (THE SCRIPPS RESEARCH INSTITUTE) 27 May 1993 see sequence no. 9 ---	1-4,9-13
X	EP,A,0 446 797 (BEHRINGWERKE) 18 September 1991 see claim 3 ---	1-13
A	WO,A,90 03390 (CORVAS, INC.) 5 April 1990 cited in the application see the whole document -----	1-13



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

4 October 1994

Date of mailing of the international search report

21.10.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Masturzo, P

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB94/01315

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 9-10, 12 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/GB 94/01315

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9309804	27-05-93	NONE	
EP-A-0446797	18-09-91	DE-A- 4007902	19-09-91
		AU-A- 7275891	19-09-91
		JP-A- 4217996	07-08-92
		US-A- 5254672	19-10-93
WO-A-9003390	05-04-90	AU-A- 4338689	18-04-90
		EP-A- 0391999	17-10-90

